Catalent Inc Stock News

Rachel Elfman, Morningstar Equity Analyst joins Romaine Bostick to discuss the big movers on the back of analyst recommendations on Bloomberg Markets: The Close. Follow Bloomberg for business news & a

Catalent has seen its share price implode over the last year. The company has seen operational weakness, just when it added quite some debt to pursue bolt-on dealmaking.

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today

A pair of prognosticators pinged the company with price target cuts. One of the two went as far as to downgrade his recommendation, too.

Investors expecting the contract drug specialist to publish its latest quarterly results on Tuesday were sorely disappointed. Once it does release results, the company will deliver weaker guidance tha

A biotechnology firm that can't catch a break, Catalent (NYSE: CTLT ) added to its growing list of problems with a delay of its fiscal third-quarter earnings report. Originally, management scheduled t

Markets were mixed just after midday on Monday. Catalent delayed a key quarterly report filing, pointing to a big hit to revenue and profit.

Catalent anticipates a significant reduction to both its fiscal 2023 revenue and adjusted earnings before interest, taxes, depreciation and amortization guidance.

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will be delaying th

Drugmaker Catalent saw production challenges a company of its caliber shouldn't be facing. Enphase Energy's current quarter isn't as healthy as expected, but the solar power evolution is still strong.

April turned out to be great month for most S&P 500 investors. But it was stupendous for those who picked the best stocks.

Catalent (CTLT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in

The contract drug manufacturer's awful April continued with a new analyst price target cut. Bank of America reduced its level by nearly 40%.

Catalent: A Promising Upside Opportunity In Play Despite Current Woes.

A pair of analysts cut their price targets on the shares. One of the cuts was rather aggressive.